SCHEMBL6288129

SCHEMBL6288129

COc1ccc(-c2nc3cccnc3[nH]2)cc1NC(=O)N(S)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CDK4 P11802 1/20 0.41
CCND1 P24385 1/20 0.41
THRB P10828 1/20 0.40
VCP P55072 1/20 0.40
AMY1A P0DUB6 2/20 0.39
IGF1R P08069 1/20 0.39
GSK3B P49841 1/20 0.39
MAPK1 P28482 1/20 0.39
ACLY P53396 1/20 0.38
TP53 P04637 4/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HPSE Q9Y251 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6288126 0.88 AMY1A (0.40) MAPTKMT2AMEN1ALDH1A1KDM4E
SCHEMBL6286254 0.88 GSK3B (0.44) MAPTKMT2AMEN1ALDH1A1KDM4E
SCHEMBL6286108 0.87 AMY1A (0.38) MAPTKMT2AMEN1ALDH1A1KDM4E
SCHEMBL6286030 0.85 ALDH1A1 (0.53) MAPTKMT2AMEN1ALDH1A1KDM4E
SCHEMBL6279221 0.85 RIPK1 (0.52) IGF1RMAPK1
SCHEMBL6711333 0.83 AMY1A (0.43) MAPTKMT2AMEN1ALDH1A1KDM4E
SCHEMBL6286006 0.83 CCNB2 (0.44) KMT2AMEN1ALDH1A1NPSR1GSK3B
SCHEMBL6288173 0.82 ACLY (0.38) MAPTKMT2AMEN1ALDH1A1KDM4E
SCHEMBL6286122 0.80 CDK4 (0.49) MAPTKMT2AMEN1ALDH1A1KDM4E
SCHEMBL6288128 0.80 KMT2A (0.52) MAPTKMT2AMEN1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US claimed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP claimed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO claimed
US-6943174-B2 6,5-Fused bicyclic heterocycles WARNER-LAMBERT COMPANY (US) 2005-09-13 US disclosed
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US disclosed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP disclosed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014759-A1 6,5-Fused bicyclic heterocycles ALOX15, ALOX5, ALOX15B MAPT 4625/4885KMT2A 4200/4885MEN1 3508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.